Amorim, Sandy <br/><br/>
Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study.  [electronic resource] 

 -  The Lancet. Haematology  Apr 2016 
 - e196-204 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>2352-3026 
<br/><br/><label>Standard No.: </label>10.1016/S2352-3026(16)00021-1  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Acetanilides--administration & dosage<br/>Aged<br/>Antineoplastic Agents--administration & dosage<br/>Drug Administration Schedule<br/>Female<br/>France<br/>Heterocyclic Compounds, 3-Ring--administration & dosage<br/>Humans<br/>Italy<br/>Lymphoma--drug therapy<br/>Male<br/>Maximum Tolerated Dose<br/>Middle Aged<br/>Multiple Myeloma--drug therapy<br/>Switzerland<br/>United Kingdom